查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1880669

肠外抗生素市场规模、占有率、成长及全球产业分析：依类型、应用和地区划分的洞察与预测（2024-2032 年）

Parenteral Antibiotics Market Size, Share, Growth and Global Industry Analysis By Type & Application, Regional Insights and Forecast to 2024-2032
出版日期: | 出版商: Fortune Business Insights Pvt. Ltd. | 英文 186 Pages | 商品交期: 请询问到货日

价格

肠外抗生素市场成长推动因素

随着医院和重症监护机构越来越依赖静脉注射 (IV) 和肌肉注射 (IM) 抗生素製剂来治疗严重感染，全球肠外抗生素市场持续扩张。最新评估显示，受住院人数增加、多重抗药性感染流行以及肠外抗生素在重症监护环境中广泛使用等因素驱动，该市场在 2024 年的规模将达到 242.2 亿美元。预计到 2025 年，该市场规模将成长至 250.9 亿美元，长期预测到 2032 年将达到 336.6 亿美元，预测期内复合年增长率 (CAGR) 为 4.3%。

北美将继续维持其主导地位，到2024年将占全球市场45.5%的占有率（价值110.2亿美元）。该地区强大的临床基础设施、先进的诊断能力以及在重症监护环境中频繁使用肠外疗法，持续推动市场需求的成长。辉瑞、葛兰素史克、艾伯维、默克、拜耳和百时美施贵宝等全球主要公司正透过产品上市、仿製药扩张和抗菌药物创新，在塑造市场趋势方面发挥关键作用。

市场动态

市场推动因素

市场成长的主要推动因素是因肺炎、败血症、脑膜炎、泌尿道感染和手术部位感染等严重感染而住院率的上升。医院获得性感染（HAI）显着增加了对肠外疗法的需求，尤其是在重症监护病房。根据世界卫生组织的数据，全球十分之一的住院患者会感染医院获得性感染，显示人们对肠外抗生素的依赖性日益增强。

另一个重要的推动因素是免疫功能低下患者数量的增加，例如癌症患者、移植患者和爱滋病毒/爱滋病患者，他们需要快速、有效率的抗生素干预。门诊静脉抗生素治疗（OPAT）的出现也促进了市场扩张，使患者能够在传统医院环境之外接受静脉抗生素治疗。

市场限制因子

新兴市场抗生素的取得障碍阻碍了市场成长。医疗基础设施薄弱、冷链设施有限以及高昂的自付费用降低了高品质注射药物的可及性。对特定国家活性药物成分（API）的依赖使全球供应链面临供应中断和价格波动的风险。

此外，抗生素研发的低利润率仍然是一个挑战。疗程短、使用限制严格以及监管流程限制了製药业的投资回报，并阻碍了创新。

市场机会

门诊抗生素治疗 (OPAT) 计画的快速发展为提供经济高效的肠外抗生素提供了巨大的机会。研究表明，与住院治疗相比，OPAT 可降低 22% 至 42% 的治疗成本，同时提高患者舒适度并释放医院资源。支付方对 OPAT 的支持力度加大以及家庭医疗保健模式的兴起，将为製造商创造新的收入机会。

市场挑战

肠外抗生素的监管壁垒和复杂的批准要求延长了研发週期并增加了生产成本。此外，全球范围内减少不必要抗生素使用的努力可能会限制某些地区的销售量成长。

主要区隔市场特征

依药物类别

截至2024年，青霉素类药物凭藉其广泛的可及性、临床疗效和不断提高的仿製药渗透率，占市场主导地位。头孢菌素类药物也将继续保持较大的市场占有率，因为它们在多种感染类型中具有广泛的临床应用。预计到2032年，大环内酯类、氟喹诺酮类和氨基糖苷类药物的市占率将稳定成长。

依应用领域

2024年，呼吸道感染领域占最大的市场占有率，这主要得益于肺炎、结核病和鼻窦炎病例的增加。泌尿道感染（UTI）领域紧随其后，这得益于针对复杂性泌尿道感染和医院获得性病原体的产品上市。

依分销管道

截至2024年，医院药局在静脉注射抗生素的管理中发挥核心作用，占市场主导地位。由于数位化进程的推进和家庭医疗保健的普及，预计线上药局领域将实现最快成长。

区域洞察

北美

北美市场预计将在2024年达到110.2亿美元，凭藉强有力的抗生素管理计划、先进的诊断技术以及创新註射药物的快速普及，预计将继续保持领先地位。

欧洲

欧洲则位居第二，这得益于较高的抗生素使用率和强而有力的监管。製造商之间的合作关係不断巩固市场地位。

亚太地区

预计亚太地区将实现最快成长。注射用抗生素获批数量的增加、高传染病负担以及庞大的人口规模正在推动该地区的需求增长。

拉丁美洲、中东和非洲

随着宣传活动的扩展和政府抗生素指南的加强，预计这些地区的需求将出现温和增长。

如果您需要，我们也提供SEO优化的HTML版本、详细的区域分析或依药物类别进行的比较分析。

目录

第一章：引言

第二章：摘要整理

第三章：市场动态

  • 市场推动因素
  • 市场阻碍因素
  • 市场机遇
  • 市场趋势

第四章：主要发现

  • 主要国家/地区主要疾病盛行率（2024 年）
  • 主要国家的报销情况
  • 主要公司产品线分析
  • 概述：肠外抗生素给药技术进展
  • 主要公司新产品发布
  • 主要产业趋势，包括併购和合作伙伴关係

第五章：全球注射用抗生素市场分析、洞察与预测（2019-2032）

  • 市场分析、洞察与预测 - 依药物类别划分
    • 青霉素类
    • 头孢菌素类
    • 氨基糖苷类
    • 四环素类
    • 大环内酯类
    • 氟喹诺酮类
    • 磺胺类
    • 其他
  • 市场分析、洞察与预测 - 依应用领域划分
    • 皮肤感染
    • 呼吸道感染
    • 泌尿道感染
    • 败血症
    • 胃肠道感染
    • 其他
  • 市场分析、洞察与预测 - 依销售额分割管道
    • 医院药房
    • 零售药房
    • 线上药房
  • 市场分析、洞察与预测 - 依地区划分
    • 北美
    • 欧洲
    • 亚太地区
    • 拉丁美洲
    • 中东和非洲

第六章：北美注射肠外抗生素市场分析、洞察与预测（2019-2032）

  • 依国家划分
    • 美国
    • 加拿大

第七章：欧洲注射肠外抗生素市场分析、洞察与预测（2019-2032）

  • 依国家划分
    • 美国王国
    • 德国
    • 法国
    • 西班牙
    • 义大利
    • 斯堪的纳维亚
    • 欧洲其他地区

第八章 亚太地区注射抗生素市场分析、洞察与预测（2019-2032）

  • 依国家划分
    • 日本
    • 中国
    • 印度
    • 澳大利亚
    • 东南亚
    • 亚太其他地区

第九章 拉丁美洲注射抗生素市场分析、洞察与预测（2019-2032）

  • 依国家划分
    • 巴西
    • 墨西哥
    • 拉丁美洲其他地区美国

第十章：中东和非洲注射抗生素市场分析、洞察与预测（2019-2032）

  • 依国家划分
    • 海湾合作委员会 (GCC)
    • 南非
    • 中东和非洲其他地区

第十一章 竞争分析

  • 全球市占率分析（2024）
  • 公司简介
    • 百时美施贵宝公司
    • 辉瑞公司
    • 山德士集团
    • 葛兰素史克公司
    • 拜耳股份公司
    • 默克公司
    • 西普拉製药
    • 艾伯维公司
    • 艾德瓦凯製药
Product Code: FBI113796

Growth Factors of parenteral antibiotics Market

The global parenteral antibiotics market continues to expand as hospitals and critical care centers increasingly rely on intravenous (IV) and intramuscular (IM) antibiotic formulations to manage severe infections. According to the latest assessment, the market was valued at USD 24.22 billion in 2024, driven by rising hospital admissions, increasing prevalence of multidrug-resistant infections, and the widespread use of injectable antibiotics in emergency care. In 2025, the market is projected to grow to USD 25.09 billion, while long-term forecasts indicate a rise to USD 33.66 billion by 2032, reflecting a CAGR of 4.3% during the forecast period.

North America held the dominant market position in 2024, accounting for 45.5% of global revenue, equivalent to USD 11.02 billion. The region's strong clinical infrastructure, high diagnostic capabilities, and frequent use of parenteral therapies in intensive care settings continue to fuel demand. Major global companies-including Pfizer Inc., GSK plc, AbbVie Inc., Merck & Co., Inc., Bayer AG, and Bristol-Myers Squibb Company-play a significant role in shaping market performance through product launches, generic expansion, and antimicrobial innovation.

Market Dynamics

Market Drivers

A key driver of market growth is the increasing rate of hospitalizations due to severe infections, including pneumonia, septicemia, meningitis, urinary tract infections, and surgical site infections. Hospital-acquired infections (HAIs) significantly contribute to the need for parenteral therapy, especially in critical care units. According to WHO, 1 in 10 hospitalized patients worldwide is affected by HAIs, underscoring the growing reliance on injectable antibiotics.

Another strong driver is the rising population of immunocompromised patients, including cancer patients, transplant recipients, and individuals with HIV/AIDS-groups that often require rapid, high-potency antibiotic intervention. The emergence of Outpatient Parenteral Antibiotic Therapy (OPAT) also contributes to market expansion, enabling patients to receive intravenous antibiotics outside traditional hospital settings.

Market Restraints

Growth is hampered by barriers to antibiotic access in emerging markets. Weak healthcare infrastructure, limited cold-chain facilities, and high out-of-pocket expenses reduce the availability of quality parenteral medications. Dependence on select countries for active pharmaceutical ingredients (APIs) makes global supply chains vulnerable to disruptions and price fluctuations.

Additionally, the low profitability of antibiotic research and development remains a challenge. Short treatment durations, stewardship-driven restrictions, and rigorous regulatory pathways limit returns on investment, discouraging pharmaceutical innovation.

Market Opportunities

The rapid expansion of OPAT programs presents major opportunities for cost-effective parenteral antibiotic delivery. Studies have shown that OPAT can reduce treatment costs by 22%-42% compared to inpatient care, while improving patient comfort and freeing hospital resources. Growing payer support for OPAT and the rise of home-based healthcare models will create new revenue openings for manufacturers.

Market Challenges

Regulatory hurdles and complex approval requirements for injectable antibiotics prolong development timelines and increase production costs. Additionally, global efforts to reduce unnecessary antibiotic use may limit volume growth in certain regions.

Segmentation Highlights

By Drug Class

Penicillin led the market in 2024, supported by its broad availability, clinical effectiveness, and growing generic penetration. Cephalosporins also maintained a significant share due to their wide clinical application across multiple infection types. Macrolides, fluoroquinolones, and aminoglycosides are expected to record steady growth through 2032.

By Application

The respiratory infections segment held the largest share in 2024, driven by rising cases of pneumonia, tuberculosis, and sinusitis. The urinary tract infections (UTI) segment follows, supported by product introductions targeting complicated UTIs and hospital-acquired pathogens.

By Distribution Channel

Hospital pharmacies dominated the market in 2024 due to their central role in administering IV antibiotics. The online pharmacy segment is projected to grow fastest as digital adoption increases and home-based care expands.

Regional Insights

North America

Valued at USD 11.02 billion in 2024, North America will maintain leadership with strong antimicrobial stewardship programs, advanced diagnostics, and rapid adoption of innovative injectables.

Europe

Europe ranked second, supported by high antibiotic usage rates and strong regulatory oversight. Collaborative partnerships among manufacturers continue to strengthen the market landscape.

Asia Pacific

Asia Pacific is expected to grow at the fastest rate. Increasing approvals for injectable antibiotics, high infection burdens, and large populations accelerate regional demand.

Latin America & Middle East-Africa

These regions are poised for moderate growth as awareness programs expand and governments strengthen antimicrobial guidelines.

Conclusion

Growing from USD 24.22 billion in 2024 to USD 33.66 billion by 2032, the parenteral antibiotics market remains essential for managing severe infections worldwide. Rising HAIs, the adoption of OPAT, and expanding generic manufacturing will continue to shape market evolution over the next decade.

If you want, I can also prepare an SEO-optimized HTML version, regional deep-dive, or drug-class comparative analysis.

Segmentation By Drug Class

  • Penicillin
  • Cephalosporin
  • Aminoglycosides
  • Tetracycline
  • Macrolides
  • Fluoroquinolones
  • Sulfonamides
  • Others

By Application

  • Skin Infections
  • Respiratory Infections
  • Urinary Tract Infections
  • Septicemia
  • Gastrointestinal Infections
  • Others

By Distribution Channel

  • Hospital Pharmacy
  • Retail Pharmacy
  • Online Pharmacy

By Region

  • North America (By Drug Class, Application, Distribution Channel, and Country/Sub-region)
    • U.S.
    • Canada
  • Europe (By Drug Class, Application, Distribution Channel, and Country/Sub-region)
    • U.K.
    • Germany
    • France
    • Italy
    • Spain
    • Scandinavia
    • Rest of Europe
  • Asia Pacific (By Drug Class, Application, Distribution Channel, and Country/Sub-region)
    • Japan
    • China
    • India
    • Australia
    • Southeast Asia
    • Rest of Asia Pacific
  • Latin America (By Drug Class, Application, Distribution Channel, and Country/Sub-region)
    • Brazil
    • Mexico
    • Rest of Latin America
  • Middle East & Africa (By Drug Class, Application, Distribution Channel, and Country/Sub-region)
    • GCC
    • South Africa
    • Rest of the Middle East & Africa

Table of Content

1. Introduction

  • 1.1. Research Scope
  • 1.2. Market Segmentation
  • 1.3. Research Methodology
  • 1.4. Definitions and Assumptions

2. Executive Summary

3. Market Dynamics

  • 3.1. Market Drivers
  • 3.2. Market Restraints
  • 3.3. Market Opportunities
  • 3.4. Market Trends

4. Key Insights

  • 4.1. Prevalence of Key Diseases, By Key Countries/Regions, 2024
  • 4.2. Reimbursement Scenario, By Key Countries/Regions
  • 4.3. Pipeline Analysis, By Key Players
  • 4.4. Overview: Technological Advancements in Parenteral Antibiotics Delivery
  • 4.5. New Product Launches, By Key Players
  • 4.6. Key Industry Developments Such as Mergers, Acquisitions, and Partnerships

5. Global Parenteral Antibiotics Market Analysis, Insights and Forecast, 2019-2032

  • 5.1. Market Analysis, Insights and Forecast - By Drug Class
    • 5.1.1. Penicillin
    • 5.1.2. Cephalosporin
    • 5.1.3. Aminoglycosides
    • 5.1.4. Tetracycline
    • 5.1.5. Macrolides
    • 5.1.6. Fluoroquinolones
    • 5.1.7. Sulfonamides
    • 5.1.8. Others
  • 5.2. Market Analysis, Insights and Forecast - By Application
    • 5.2.1. Skin Infections
    • 5.2.2. Respiratory Infections
    • 5.2.3. Urinary Tract Infections
    • 5.2.4. Septicemia
    • 5.2.5. Gastrointestinal Infections
    • 5.2.6. Others
  • 5.3. Market Analysis, Insights and Forecast - By Distribution Channel
    • 5.3.1. Hospital Pharmacy
    • 5.3.2. Retail Pharmacy
    • 5.3.3. Online Pharmacy
  • 5.4. Market Analysis, Insights and Forecast - By Region
    • 5.4.1. North America
    • 5.4.2. Europe
    • 5.4.3. Asia Pacific
    • 5.4.4. Latin America
    • 5.4.5. Middle East & Africa

6. North America Parenteral Antibiotics Market Analysis, Insights and Forecast, 2019-2032

  • 6.1. Market Analysis, Insights and Forecast - By Drug Class
    • 6.1.1. Penicillin
    • 6.1.2. Cephalosporin
    • 6.1.3. Aminoglycosides
    • 6.1.4. Tetracycline
    • 6.1.5. Macrolides
    • 6.1.6. Fluoroquinolones
    • 6.1.7. Sulfonamides
    • 6.1.8. Others
  • 6.2. Market Analysis, Insights and Forecast - By Application
    • 6.2.1. Skin Infections
    • 6.2.2. Respiratory Infections
    • 6.2.3. Urinary Tract Infections
    • 6.2.4. Septicemia
    • 6.2.5. Gastrointestinal Infections
    • 6.2.6. Others
  • 6.3. Market Analysis, Insights and Forecast - By Distribution Channel
    • 6.3.1. Hospital Pharmacy
    • 6.3.2. Retail Pharmacy
    • 6.3.3. Online Pharmacy
  • 6.4. Market Analysis, Insights and Forecast - By Country
    • 6.4.1. U.S.
    • 6.4.2. Canada

7. Europe Parenteral Antibiotics Market Analysis, Insights and Forecast, 2019-2032

  • 7.1. Market Analysis, Insights and Forecast - By Drug Class
    • 7.1.1. Penicillin
    • 7.1.2. Cephalosporin
    • 7.1.3. Aminoglycosides
    • 7.1.4. Tetracycline
    • 7.1.5. Macrolides
    • 7.1.6. Fluoroquinolones
    • 7.1.7. Sulfonamides
    • 7.1.8. Others
  • 7.2. Market Analysis, Insights and Forecast - By Application
    • 7.2.1. Skin Infections
    • 7.2.2. Respiratory Infections
    • 7.2.3. Urinary Tract Infections
    • 7.2.4. Septicemia
    • 7.2.5. Gastrointestinal Infections
    • 7.2.6. Others
  • 7.3. Market Analysis, Insights and Forecast - By Distribution Channel
    • 7.3.1. Hospital Pharmacy
    • 7.3.2. Retail Pharmacy
    • 7.3.3. Online Pharmacy
  • 7.4. Market Analysis, Insights and Forecast - By Country/Sub-region
    • 7.4.1. U.K.
    • 7.4.2. Germany
    • 7.4.3. France
    • 7.4.4. Spain
    • 7.4.5. Italy
    • 7.4.6. Scandinavia
    • 7.4.7. Rest of Europe

8. Asia Pacific Parenteral Antibiotics Market Analysis, Insights and Forecast, 2019-2032

  • 8.1. Market Analysis, Insights and Forecast - By Drug Class
    • 8.1.1. Penicillin
    • 8.1.2. Cephalosporin
    • 8.1.3. Aminoglycosides
    • 8.1.4. Tetracycline
    • 8.1.5. Macrolides
    • 8.1.6. Fluoroquinolones
    • 8.1.7. Sulfonamides
    • 8.1.8. Others
  • 8.2. Market Analysis, Insights and Forecast - By Application
    • 8.2.1. Skin Infections
    • 8.2.2. Respiratory Infections
    • 8.2.3. Urinary Tract Infections
    • 8.2.4. Septicemia
    • 8.2.5. Gastrointestinal Infections
    • 8.2.6. Others
  • 8.3. Market Analysis, Insights and Forecast - By Distribution Channel
    • 8.3.1. Hospital Pharmacy
    • 8.3.2. Retail Pharmacy
    • 8.3.3. Online Pharmacy
  • 8.4. Market Analysis, Insights and Forecast - By Country/Sub-region
    • 8.4.1. Japan
    • 8.4.2. China
    • 8.4.3. India
    • 8.4.4. Australia
    • 8.4.5. Southeast Asia
    • 8.4.6. Rest of Asia Pacific

9. Latin America Parenteral Antibiotics Market Analysis, Insights and Forecast, 2019-2032

  • 9.1. Market Analysis, Insights and Forecast - By Drug Class
    • 9.1.1. Penicillin
    • 9.1.2. Cephalosporin
    • 9.1.3. Aminoglycosides
    • 9.1.4. Tetracycline
    • 9.1.5. Macrolides
    • 9.1.6. Fluoroquinolones
    • 9.1.7. Sulfonamides
    • 9.1.8. Others
  • 9.2. Market Analysis, Insights and Forecast - By Application
    • 9.2.1. Skin Infections
    • 9.2.2. Respiratory Infections
    • 9.2.3. Urinary Tract Infections
    • 9.2.4. Septicemia
    • 9.2.5. Gastrointestinal Infections
    • 9.2.6. Others
  • 9.3. Market Analysis, Insights and Forecast - By Distribution Channel
    • 9.3.1. Hospital Pharmacy
    • 9.3.2. Retail Pharmacy
    • 9.3.3. Online Pharmacy
  • 9.4. Market Analysis, Insights and Forecast - By Country/Sub-region
    • 9.4.1. Brazil
    • 9.4.2. Mexico
    • 9.4.3. Rest of Latin America

10. Middle East & Africa Parenteral Antibiotics Market Analysis, Insights and Forecast, 2019-2032

  • 10.1. Market Analysis, Insights and Forecast - By Drug Class
    • 10.1.1. Penicillin
    • 10.1.2. Cephalosporin
    • 10.1.3. Aminoglycosides
    • 10.1.4. Tetracycline
    • 10.1.5. Macrolides
    • 10.1.6. Fluoroquinolones
    • 10.1.7. Sulfonamides
    • 10.1.8. Others
  • 10.2. Market Analysis, Insights and Forecast - By Application
    • 10.2.1. Skin Infections
    • 10.2.2. Respiratory Infections
    • 10.2.3. Urinary Tract Infections
    • 10.2.4. Septicemia
    • 10.2.5. Gastrointestinal Infections
    • 10.2.6. Others
  • 10.3. Market Analysis, Insights and Forecast - By Distribution Channel
    • 10.3.1. Hospital Pharmacy
    • 10.3.2. Retail Pharmacy
    • 10.3.3. Online Pharmacy
  • 10.4. Market Analysis, Insights and Forecast - By Country/Sub-region
    • 10.4.1. GCC
    • 10.4.2. South Africa
    • 10.4.3. Rest of Middle East & Africa

11. Competitive Analysis

  • 11.1. Global Market Share Analysis (2024)
  • 11.2. Company Profiles
    • 11.2.1. Bristol-Myers Squibb Company
      • 11.2.1.1. Overview
      • 11.2.1.2. Products & services
      • 11.2.1.3. SWOT Analysis
      • 11.2.1.4. Recent Developments
      • 11.2.1.5. Strategies
      • 11.2.1.6. Financials (Based on Availability)
    • 11.2.2. Pfizer Inc.
      • 11.2.2.1. Overview
      • 11.2.2.2. Products & services
      • 11.2.2.3. SWOT Analysis
      • 11.2.2.4. Recent Developments
      • 11.2.2.5. Strategies
      • 11.2.2.6. Financials (Based on Availability)
    • 11.2.3. Sandoz Group AG
      • 11.2.3.1. Overview
      • 11.2.3.2. Products & services
      • 11.2.3.3. SWOT Analysis
      • 11.2.3.4. Recent Developments
      • 11.2.3.5. Strategies
      • 11.2.3.6. Financials (Based on Availability)
    • 11.2.4. GSK plc.
      • 11.2.4.1. Overview
      • 11.2.4.2. Products & services
      • 11.2.4.3. SWOT Analysis
      • 11.2.4.4. Recent Developments
      • 11.2.4.5. Strategies
      • 11.2.4.6. Financials (Based on Availability)
    • 11.2.5. Bayer AG
      • 11.2.5.1. Overview
      • 11.2.5.2. Products & services
      • 11.2.5.3. SWOT Analysis
      • 11.2.5.4. Recent Developments
      • 11.2.5.5. Strategies
      • 11.2.5.6. Financials (Based on Availability)
    • 11.2.6. Merck & Co., Inc.
      • 11.2.6.1. Overview
      • 11.2.6.2. Products & services
      • 11.2.6.3. SWOT Analysis
      • 11.2.6.4. Recent Developments
      • 11.2.6.5. Strategies
      • 11.2.6.6. Financials (Based on Availability)
    • 11.2.7. Cipla
      • 11.2.7.1. Overview
      • 11.2.7.2. Products & services
      • 11.2.7.3. SWOT Analysis
      • 11.2.7.4. Recent Developments
      • 11.2.7.5. Strategies
      • 11.2.7.6. Financials (Based on Availability)
    • 11.2.8. AbbVie Inc.
      • 11.2.8.1. Overview
      • 11.2.8.2. Products & services
      • 11.2.8.3. SWOT Analysis
      • 11.2.8.4. Recent Developments
      • 11.2.8.5. Strategies
      • 11.2.8.6. Financials (Based on Availability)
    • 11.2.9. AdvaCare Pharma
      • 11.2.9.1. Overview
      • 11.2.9.2. Products & services
      • 11.2.9.3. SWOT Analysis
      • 11.2.9.4. Recent Developments
      • 11.2.9.5. Strategies
      • 11.2.9.6. Financials (Based on Availability)

List of Tables

  • Table 1: Global Parenteral Antibiotics Market Revenue (USD billion) Forecast, By Drug Class, 2019-2032
  • Table 2: Global Parenteral Antibiotics Market Revenue (USD billion) Forecast, By Application, 2019-2032
  • Table 3: Global Parenteral Antibiotics Market Revenue (USD billion) Forecast, by Distribution Channel, 2019-2032
  • Table 4: Global Parenteral Antibiotics Market Revenue (USD billion) Forecast, by Region, 2019-2032
  • Table 5: North America Parenteral Antibiotics Market Revenue (USD billion) Forecast, By Drug Class, 2019-2032
  • Table 6: North America Parenteral Antibiotics Market Revenue (USD billion) Forecast, By Application, 2019-2032
  • Table 7: North America Parenteral Antibiotics Market Revenue (USD billion) Forecast, by Distribution Channel, 2019-2032
  • Table 8: North America Parenteral Antibiotics Market Revenue (USD billion) Forecast, By Country, 2019-2032
  • Table 9: Europe Parenteral Antibiotics Market Revenue (USD billion) Forecast, By Drug Class, 2019-2032
  • Table 10: Europe Parenteral Antibiotics Market Revenue (USD billion) Forecast, By Application, 2019-2032
  • Table 11: Europe Parenteral Antibiotics Market Revenue (USD billion) Forecast, by Distribution Channel, 2019-2032
  • Table 12: Europe Parenteral Antibiotics Market Revenue (USD billion) Forecast, By Country/ Sub-region, 2019-2032
  • Table 13: Asia Pacific Parenteral Antibiotics Market Revenue (USD billion) Forecast, By Drug Class, 2019-2032
  • Table 14: Asia Pacific Parenteral Antibiotics Market Revenue (USD billion) Forecast, By Application, 2019-2032
  • Table 15: Asia Pacific Parenteral Antibiotics Market Revenue (USD billion) Forecast, by Distribution Channel, 2019-2032
  • Table 16: Asia Pacific Parenteral Antibiotics Market Revenue (USD billion) Forecast, By Country/ Sub-region, 2019-2032
  • Table 17: Latin America Parenteral Antibiotics Market Revenue (USD billion) Forecast, By Drug Class, 2019-2032
  • Table 18: Latin America Parenteral Antibiotics Market Revenue (USD billion) Forecast, By Application, 2019-2032
  • Table 19: Latin America Parenteral Antibiotics Market Revenue (USD billion) Forecast, by Distribution Channel, 2019-2032
  • Table 20: Latin America Parenteral Antibiotics Market Revenue (USD billion) Forecast, By Country/ Sub-region, 2019-2032
  • Table 21: Middle East & Africa Parenteral Antibiotics Market Revenue (USD billion) Forecast, By Drug Class, 2019-2032
  • Table 22: Middle East & Africa Parenteral Antibiotics Market Revenue (USD billion) Forecast, By Application, 2019-2032
  • Table 23: Middle East & Africa Parenteral Antibiotics Market Revenue (USD billion) Forecast, by Distribution Channel, 2019-2032
  • Table 24: Middle East & Africa Parenteral Antibiotics Market Revenue (USD billion) Forecast, By Country/ Sub-region, 2019-2032

List of Figures

  • Figure 1: Global Parenteral Antibiotics Market Revenue Breakdown (USD billion, %) by Region, 2024 & 2032
  • Figure 2: Global Parenteral Antibiotics Market Value Share (%), By Drug Class, 2024 & 2032
  • Figure 3: Global Parenteral Antibiotics Market Value Share (%), By Application, 2024 & 2032
  • Figure 4: Global Parenteral Antibiotics Market Value Share (%), by Distribution Channel, 2024 & 2032
  • Figure 5: Global Parenteral Antibiotics Market Value Share (%), by Region, 2024 & 2032
  • Figure 6: North America Parenteral Antibiotics Market Value (USD billion), By Drug Class, 2024 & 2032
  • Figure 7: North America Parenteral Antibiotics Market Value Share (%), By Drug Class, 2024
  • Figure 8: North America Parenteral Antibiotics Market Value (USD billion), By Application, 2024 & 2032
  • Figure 9: North America Parenteral Antibiotics Market Value Share (%), By Application, 2024
  • Figure 10: North America Parenteral Antibiotics Market Value (USD billion), by Distribution Channel, 2024 & 2032
  • Figure 11: North America Parenteral Antibiotics Market Value Share (%), by Distribution Channel, 2024
  • Figure 12: North America Parenteral Antibiotics Market Value (USD billion), By Country, 2024 & 2032
  • Figure 13: North America Parenteral Antibiotics Market Value Share (%), By Country, 2024
  • Figure 14: Europe Parenteral Antibiotics Market Value (USD billion), By Drug Class, 2024 & 2032
  • Figure 15: Europe Parenteral Antibiotics Market Value Share (%), By Drug Class, 2024
  • Figure 16: Europe Parenteral Antibiotics Market Value (USD billion), By Application, 2024 & 2032
  • Figure 17: Europe Parenteral Antibiotics Market Value Share (%), By Application, 2024
  • Figure 18: Europe Parenteral Antibiotics Market Value (USD billion), by Distribution Channel, 2024 & 2032
  • Figure 19: Europe Parenteral Antibiotics Market Value Share (%), by Distribution Channel, 2024
  • Figure 20: Europe Parenteral Antibiotics Market Value (USD billion), By Country/ Sub-region, 2024 & 2032
  • Figure 21: Europe Parenteral Antibiotics Market Value Share (%), By Country/ Sub-region, 2024
  • Figure 22: Asia Pacific Parenteral Antibiotics Market Value (USD billion), By Drug Class, 2024 & 2032
  • Figure 23: Asia Pacific Parenteral Antibiotics Market Value Share (%), By Drug Class, 2024
  • Figure 24: Asia Pacific Parenteral Antibiotics Market Value (USD billion), By Application, 2024 & 2032
  • Figure 25: Asia Pacific Parenteral Antibiotics Market Value Share (%), By Application, 2024
  • Figure 26: Asia Pacific Parenteral Antibiotics Market Value (USD billion), by Distribution Channel, 2024 & 2032
  • Figure 27: Asia Pacific Parenteral Antibiotics Market Value Share (%), by Distribution Channel, 2024
  • Figure 28: Asia Pacific Parenteral Antibiotics Market Value (USD billion), By Country/ Sub-region, 2024 & 2032
  • Figure 29: Asia Pacific Parenteral Antibiotics Market Value Share (%), By Country/ Sub-region, 2024
  • Figure 30: Latin America Parenteral Antibiotics Market Value (USD billion), By Drug Class, 2024 & 2032
  • Figure 31: Latin America Parenteral Antibiotics Market Value Share (%), By Drug Class, 2024
  • Figure 32: Latin America Parenteral Antibiotics Market Value (USD billion), By Application, 2024 & 2032
  • Figure 33: Latin America Parenteral Antibiotics Market Value Share (%), By Application, 2024
  • Figure 34: Latin America Parenteral Antibiotics Market Value (USD billion), by Distribution Channel, 2024 & 2032
  • Figure 35: Latin America Parenteral Antibiotics Market Value Share (%), by Distribution Channel, 2024
  • Figure 36: Latin America Parenteral Antibiotics Market Value (USD billion), By Country/ Sub-region, 2024 & 2032
  • Figure 37: Latin America Parenteral Antibiotics Market Value Share (%), By Country/ Sub-region, 2024
  • Figure 38: Middle East & Africa Parenteral Antibiotics Market Value (USD billion), By Drug Class, 2024 & 2032
  • Figure 39: Middle East & Africa Parenteral Antibiotics Market Value Share (%), By Drug Class, 2024
  • Figure 40: Middle East & Africa Parenteral Antibiotics Market Value (USD billion), By Application, 2024 & 2032
  • Figure 41: Middle East & Africa Parenteral Antibiotics Market Value Share (%), By Application, 2024
  • Figure 42: Middle East & Africa Parenteral Antibiotics Market Value (USD billion), by Distribution Channel, 2024 & 2032
  • Figure 43: Middle East & Africa Parenteral Antibiotics Market Value Share (%), by Distribution Channel, 2024
  • Figure 44: Middle East & Africa Parenteral Antibiotics Market Value (USD billion), By Country/ Sub-region, 2024 & 2032
  • Figure 45: Middle East & Africa Parenteral Antibiotics Market Value Share (%), By Country/ Sub-region, 2024
  • Figure 46: Global Parenteral Antibiotics Market Share (%), By Company, 2024